Our 3rd an­nu­al UK bio­phar­ma event tops this week — on Zoom — with José Basel­ga, top biotech CEOs and a look at the glob­al fi­nan­cial scene

The first few years of Pas­cal So­ri­ot’s reign as CEO of As­traZeneca were tough to watch, at times. Set­backs were more com­mon than break­throughs, and its in­abil­i­ty to fin­ish its new head­quar­ters build­ing in Cam­bridge, UK, seemed em­blem­at­ic of its in­ner con­fu­sion. True, So­ri­ot had in­her­it­ed the worst pipeline in Big Phar­ma, but in­vestors fret­ted for some time when the com­pa­ny would get back on track.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER